Page 7 - Robert Iannone News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jazz Pharma Expands Neuroscience Pipeline with $7.2B GW Acquisition February 4, 2021 Jazz Pharmaceuticals has put its proverbial money where its mouth is about expanding its neuroscience pipeline beyond sleep disorders—a goal the company discussed with GEN last month—with its planned $7.2 billion acquisition of cannabinoid-based drug developer GW Pharmaceuticals. [Leterrier, NeuroCyto Lab, INP, Marseille, France] Share GEN last month—with its planned $7.2 billion acquisition of cannabinoid-based drug developer GW Pharmaceuticals. The deal, announced Wednesday, would create a combined co...

Share this article Share this article DUBLIN, Dec. 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has initiated the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for JZP-458 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.  The BLA was...